Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProTarget
NCT04341181Phase 2Recruiting
- Sponsor
- Lassen Therapeutics
- Start
- Aug 2020
- Primary completion
- Apr 2029
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of alectinib, atezolizumab, avelumab, axitinib, erlotinib and 7 more in solid tumor (advanced stage), multiple myeloma (MM) and B-cell non-Hodgkin lymphoma (10 arms), sponsored by Lassen Therapeutics. Primary endpoint: Objective Tumor Response or Stable Disease at 16 weeks. Started Aug 2020; status: recruiting.
02
Drugs
alectinibatezolizumabavelumabaxitiniberlotinib
03
Conditions
solid tumor (advanced stage)multiple myeloma (MM)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04341181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04341181.